Torrent Pharma announced a partnership with Takeda Pharma to sell Vonoprazan, a treatment for gastroesophageal reflux disease (GERD), in India. Torrent will market the drug under the name Kabvie.
A 2019 study showed that GERD affects about 8.2% of Indians, with urban areas seeing rates as high as 11.1%. The Indian market for GERD treatments is worth Rs 8,064 crore and has been growing at 8% annually.
Currently, GERD is mainly treated with proton pump inhibitors like pantoprazole. Torrent stated that Kabvie will offer a new, effective treatment option for GERD. Aman Mehta, a director at Torrent, said the launch will help reduce the GERD burden and strengthen the company’s position in the Indian pharmaceutical market.
Disclaimer: The views and investment tips expressed by investment experts on Sharepriceindia.com are their own and not those of the website or its management. Sharepriceindia.com advises users to check with certified experts before taking any investment decisions.
